Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP Trimers

Journal of Virology

Volumn 91, Issue 15, 2017, Pages

  Ringe, Rajesh P ^a   Ozorowski, Gabriel ^b   Rantalainen, Kimmo ^b   Struwe, Weston B ^c   Matthews, Katie ^a,f   Torres, Jonathan L ^b   Yasmeen, Anila ^a   Cottrell, Christopher A ^b   Ketas, Thomas J ^a   LaBranche, Celia C ^d   Montefiori, David C ^b   Cupo, Albert ^a   Crispin, Max ^b,c   Wilson, Ian A ^b   Ward, Andrew B ^b   Sanders, Rogier W ^a,e   Klasse, P J ^a   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f Innovimmune Biotherapeutics Inc   (United States)

Author keywords

Env trimers; HIV 1 vaccine; V3 region

Indexed keywords

ANTIBODY; EPITOPE; GLYCAN DERIVATIVE; NONNEUTRALIZING ANTIBODY; POLYMER; SOLUBLE CD4 ANTIGEN; SOSIP TRIMER; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; ORYCTOLAGUS CUNICULUS; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS ENVELOPE; ANIMAL; BLOOD; GENETICS; GLYCOSYLATION; HUMAN; IMMUNOLOGY; POPULATION GROUP; PROTEIN PROCESSING; RABBITS AND HARES;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES, B-LYMPHOCYTE; GLYCOSYLATION; HIV ANTIBODIES; HIV-1; HUMANS; POPULATION GROUPS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RABBITS;

EID: 85023203355     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00677-17     Document Type: Article

References (50)

1. Julien JP, Lee JH, Ozorowski G, Hua Y, Torrents de la Pena A, de Taeye SW, Nieusma T, Cupo A, Yasmeen A, Golabek M, Pugach P, Klasse PJ, Moore JP, Sanders RW, Ward AB, Wilson IA. 2015. Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proc Natl Acad Sci U S A 112:11947-11952. https://doi.org/10.1073/pnas.1507793112
2. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342: 1477-1483. https://doi.org/10.1126/science.1245625
3. Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, Lee KK, Wilson IA, Butera ST, Ward AB, Montefiori DC, Sanders RW, Moore JP. 2016. Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP.664 trimers from clades A, B and C. PLoS Pathog 12:e1005864. https://doi.org/10.1371/journal.ppat.1005864
4. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. 2013. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210:655-663. https://doi.org/10.1084/jem.20122824
5. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9:e1003618. https://doi.org/10.1371/journal.ppat.1003618
6. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramirez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. 2015. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349:aac4223. https://doi.org/10.1126/science.aac4223
7. Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, Huang X, Kulp D, Osawa K, Muranaka J, Stewart-Jones G, Destefano J, O'Dell S, LaBranche C, Robinson JE, Montefiori DC, McKee K, Du SX, Doria-Rose N, Kwong PD, Mascola JR, Zhu P, Schief WR, Wyatt RT, Whalen RG, Binley JM. 2015. Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site. PLoS Pathog 11:e1004932. https://doi.org/10.1371/ journal.ppat.1004932
8. Tong T, Crooks ET, Osawa K, Binley JM. 2012. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 86:3574-3587. https://doi.org/10.1128/ JVI.06938-11
9. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. 2014. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455-461. https://doi.org/10.1038/ nature13808
10. Chung NP, Matthews K, Kim HJ, Ketas TJ, Golabek M, de Los Reyes K, Korzun J, Yasmeen A, Sanders RW, Klasse PJ, Wilson IA, Ward AB, Marozsan AJ, Moore JP, Cupo A. 2014. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology 11:33. https://doi.org/10.1186/ 1742-4690-11-33
11. Sanders RW, Moore JP. 2017. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev 275:161-182. https://doi.org/10.1111/imr.12481
12. Ringe RP, Ozorowski G, Yasmeen A, Cupo A, Cruz Portillo VM, Pugach P, Golabek M, Rantalainen K, Holden LG, Cottrell CA, Wilson IA, Sanders RW, Ward AB, Klasse PJ, Moore JP. 5 April 2017. Improving the expression and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers by targeted sequence changes. J Virol https://doi.org/10.1128/JVI.00264-17
13. Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW, Cupo A, Crispin M, Lee KK, Desaire H, Ward AB, Klasse PJ, Moore JP. 2015. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers. J Virol 89:12189-12210. https://doi.org/10.1128/JVI.01768-15
14. Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP. 2015. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol 89:3380-3395. https://doi.org/10.1128/JVI.03473-14
15. de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW. 2015. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163: 1702-1715. https://doi.org/10.1016/j.cell.2015.11.056
16. Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou T, Ahlsen G, Bailer RT, Chambers M, Chuang GY, Doria-Rose NA, Druz A, Hallen MA, Harned A, Kirys T, Louder MK, O'Dell S, Ofek G, Osawa K, Prabhakaran M, Sastry M, Stewart-Jones GB, Stuckey J, Thomas PV, Tittley T, Williams C, Zhang B, Zhao H, Zhou Z, Donald BR, Lee LK, Zolla-Pazner S, Baxa U, Schon A, Freire E, Shapiro L, Lee KK, Arthos J, Munro JB, Blanchard SC, Mothes W, Binley JM, McDermott AB, Mascola JR, Kwong PD. 2015. Crystal structure, conformational fixation and entryrelated interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol 22:522-531. https://doi.org/10.1038/nsmb.3051
17. Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens AJ, Bylund T, Choi CW, Davison JR, Georgiev IS, Joyce MG, Kwon YD, Pancera M, Taft J, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CC, Wu CY, Bewley CA, Burton DR, Koff WC, Connors M, Crispin M, Baxa U, Korber BT, Wong CH, Mascola JR, Kwong PD. 2016. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165:813-826. https://doi.org/10.1016/j.cell.2016.04.010
18. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A 108:11440-11445. https://doi.org/10.1073/pnas.1101414108
19. Lee JH, Ozorowski G, Ward AB. 2016. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043-1048. https://doi.org/10.1126/science.aad2450
20. Ward AB, Wilson IA. 2017. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol Rev 275:21-32. https://doi.org/ 10.1111/imr.12507
21. Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ. 2014. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 11:41. https://doi.org/10.1186/1742-4690-11-41
22. Cheng C, Pancera M, Bossert A, Schmidt SD, Chen RE, Chen X, Druz A, Narpala S, Doria-Rose NA, McDermott AB, Kwong PD, Mascola JR. 2015. Immunogenicity of a prefusion HIV-1 envelope trimer in complex with a quaternary-structure-specific antibody. J Virol 90:2740-2755. https://doi.org/10.1128/JVI.02380-15
23. Chuang GY, Geng H, Pancera M, Xu K, Cheng C, Acharya P, Chambers M, Druz A, Tsybovsky Y, Wanninger TG, Yang Y, Doria-Rose NA, Georgiev IS, Gorman J, Joyce MG, O'Dell S, Zhou T, McDermott AB, Mascola JR, Kwong PD. 8 March 2017. Structure-based design of a soluble prefusionclosed HIV-1-Env trimer with reduced CD4 affinity and improved immunogenicity. J Virol https://doi.org/10.1128/JVI.02268-16
24. Havenar-Daughton C, Lee JH, Crotty S. 2017. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol Rev 275:49-61. https://doi.org/10.1111/imr.12512
25. McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L. 2014. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346: 1380-1383. https://doi.org/10.1126/science.1259206
26. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit J, Nara PL. 1997. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159:279-289
27. Eggink D, Goff PH, Palese P. 2014. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J Virol 88:699-704. https://doi.org/10.1128/JVI.02608-13
28. Sliepen K, van Montfort T, Melchers M, Isik G, Sanders RW. 2015. Immunosilencing a highly immunogenic protein trimerization domain. J Biol Chem 290:7436-7442. https://doi.org/10.1074/jbc.M114.620534
29. Behrens AJ, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M. 2017. Molecular architecture of the cleavagedependent mannose patch on a soluble HIV-1 envelope glycoprotein trimer. J Virol 91:e01894-16. https://doi.org/10.1128/JVI.01894-16
30. Behrens AJ, Crispin M. 2017. Structural principles controlling HIV envelope glycosylation. Curr Opin Struct Biol 44:125-133. https://doi.org/10.1016/j.sbi.2017.03.008
31. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB 3rd, Kwong PD, Blanchard SC, Mothes W. 2014. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346:759-763. https://doi.org/10.1126/science.1254426
32. Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L, Wu NC, McBride R, Sok D, Pauthner M, Cottrell CA, Nieusma T, Blattner C, Paulson JC, Klasse PJ, Wilson IA, Burton DR, Ward AB. 2017. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity 46:690-702. https://doi.org/10.1016/j.immuni.2017.03.017
33. Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S. 2015. Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. J Virol 89:10383-10398. https://doi.org/10.1128/JVI.01653-15
34. Forsell MN, Soldemo M, Dosenovic P, Wyatt RT, Karlsson MC, Karlsson Hedestam GB. 2013. Independent expansion of epitope-specific plasma cell responses upon HIV-1 envelope glycoprotein immunization. J Immunol 191:44-51. https://doi.org/10.4049/jimmunol.1203087
35. Stamatatos L, Pancera M, McGuire AT. 2017. Germline-targeting immunogens. Immunol Rev 275:203-216. https://doi.org/10.1111/imr.12483
36. Medina-Ramirez M, Garces F, Escolano A, Skog P, Del Moral-Sanchez I, Dosenovic P, Hua Y, McGuire AT, Gitlin AD, Freund NT, Yasmeen A, Behrens AJ, Ozorowski G, de Taeye SW, van den Kerkhof TL, Sliepen K, Blane T, Kootstra NA, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med, in press
37. Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ. 2016. Structural basis for germline antibody recognition of HIV-1 immunogens. eLife 5:e13783. https://doi.org/10.7554/eLife.13783
38. Escolano A, Dosenovic P, Nussenzweig MC. 2017. Progress toward active or passive HIV-1 vaccination. J Exp Med 214:3-16. https://doi.org/10.1084/jem.20161765
39. Victora GD, Nussenzweig MC. 2012. Germinal centers. Annu Rev Immunol 30:429-457. https://doi.org/10.1146/annurev-immunol-020711-075032
40. Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, Young SP, Reynolds A, Falciani F, Waisman A, Notley CA, Ehrenstein MR, Kosco-Vilbois M, Toellner KM. 2013. Germinal center B cells govern their own fate via antibody feedback. J Exp Med 210:457-464. https://doi.org/ 10.1084/jem.20120150
41. McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L. 2016. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 7:10618. https://doi.org/10.1038/ncomms10618
42. Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N, Seabright GE, Kramer HB, Spencer DI, Royle L, Lee JH, Klasse PJ, Burton DR, Wilson IA, Ward AB, Sanders RW, Moore JP, Doores KJ, Crispin M. 2016. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep 14:2695-2706. https://doi.org/10.1016/j.celrep.2016.02.058
43. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC
44. Chung KY, Coyle EM, Jani D, King LR, Bhardwaj R, Fries L, Smith G, Glenn G, Golding H, Khurana S. 2015. ISCOMATRIX adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine 33:3953-3962. https://doi.org/10.1016/j.vaccine.2015.06.047
45. Montefiori DC. 2009. Measuring HIV neutralization in a luciferase re-porter gene assay. Methods Mol Biol 485:395-405. https://doi.org/10.1007/978-1-59745-170-3_26
46. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. https://doi.org/ 10.1128/AAC.46.6.1896-1905.2002
47. Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338:182-199. https://doi.org/10.1016/j.virol.2005.04.035
48. Kaplan HA, Welply JK, Lennarz WJ. 1987. Oligosaccharyl transferase: the central enzyme in the pathway of glycoprotein assembly. Biochim Biophys Acta 906:161-173. https://doi.org/10.1016/0304-4157(87)90010-4
49. van den Kerkhof TL, Feenstra KA, Euler Z, van Gils MJ, Rijsdijk LW, Boeser-Nunnink BD, Heringa J, Schuitemaker H, Sanders RW. 2013. HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology 10:102. https://doi.org/10.1186/1742-4690-10-102
50. Gavel Y, von Heijne G. 1990. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering. Protein Eng 3:433-442. https://doi.org/10.1093/ protein/3.5.433